These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 24184931)

  • 1. [Long-term treatment with intravitreal ranibizumab for exudative age-related macular degeneration].
    Lukács R; Resch M; Papp A; Szabó A; Borbándy Á; Menkens H; Kiss H; Németh J
    Orv Hetil; 2013 Nov; 154(45):1790-7. PubMed ID: 24184931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
    Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
    Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treat and Extend versus Pro Re Nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 Month study.
    Hatz K; Prünte C
    Acta Ophthalmol; 2017 Feb; 95(1):e67-e72. PubMed ID: 27009503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy with low-dose transpupillary thermotherapy and intravitreal ranibizumab for neovascular age-related macular degeneration: a 24-month prospective randomised clinical study.
    Söderberg AC; Algvere PV; Hengstler JC; Söderberg P; Seregard S; Kvanta A
    Br J Ophthalmol; 2012 May; 96(5):714-8. PubMed ID: 22241923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-year follow-up of a pilot study of ranibizumab combined with proton beam irradiation as treatment for exudative age-related macular degeneration.
    Park SS; Daftari I; Phillips T; Morse LS
    Retina; 2012 May; 32(5):956-66. PubMed ID: 22183743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visual acuity outcomes in ranibizumab-treated neovascular age-related macular degeneration; stratified by baseline vision.
    Shona O; Gupta B; Vemala R; Sivaprasad S
    Clin Exp Ophthalmol; 2011 Jan; 39(1):5-8. PubMed ID: 21040311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration.
    Simader C; Ritter M; Bolz M; Deák GG; Mayr-Sponer U; Golbaz I; Kundi M; Schmidt-Erfurth UM
    Ophthalmology; 2014 Jun; 121(6):1237-45. PubMed ID: 24684838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal ranibizumab for naive extrafoveal choroidal neovascularization secondary to age-related macular degeneration.
    Parodi MB; Iacono P; La Spina C; Iuliano L; Lo Giudice G; Introini U; Bandello F
    Retina; 2014 Nov; 34(11):2167-70. PubMed ID: 24999724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
    Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G;
    Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early visual impacts of optical coherence tomographic parameters in patients with age-related macular degeneration following the first versus repeated ranibizumab injection.
    Sayed KM; Naito T; Nagasawa T; Katome T; Mitamura Y
    Graefes Arch Clin Exp Ophthalmol; 2011 Oct; 249(10):1449-58. PubMed ID: 21494878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab.
    Cho HJ; Kim CG; Yoo SJ; Cho SW; Lee DW; Kim JW; Lee JH
    Am J Ophthalmol; 2013 Jan; 155(1):118-126.e1. PubMed ID: 23022163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
    Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
    Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
    Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
    Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
    Brown DM; Chen E; Mariani A; Major JC;
    Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of intravitreal ranibizumab in phakic and pseudophakic neovascular age-related macular degeneration patients with good baseline visual acuity.
    Ozkaya A; Alkin Z; Yazici AT; Demirok A
    Retina; 2014 May; 34(5):853-9. PubMed ID: 24141904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity.
    Saito M; Iida T; Kano M
    Retina; 2012 Jul; 32(7):1250-9. PubMed ID: 22446886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of intravitreal ranibizumab with a prn regimen in the treatment of extrafoveal and juxtafoveal neovascular membranes in age-related macular degeneration.
    Giacomelli G; Giansanti F; Finocchio L; Biagini I; Bacherini D; Virgili G; Menchini U
    Retina; 2014 May; 34(5):860-7. PubMed ID: 24756034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany.
    Finger RP; Wiedemann P; Blumhagen F; Pohl K; Holz FG
    Acta Ophthalmol; 2013 Sep; 91(6):540-6. PubMed ID: 23171290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis.
    Canan H; Sızmaz S; Altan-Yaycıoğlu R; Sarıtürk C; Yılmaz G
    Clin Interv Aging; 2014; 9():141-5. PubMed ID: 24453484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
    Ho AC; Busbee BG; Regillo CD; Wieland MR; Van Everen SA; Li Z; Rubio RG; Lai P;
    Ophthalmology; 2014 Nov; 121(11):2181-92. PubMed ID: 25015215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.